Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line
Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher, Orazio Caffo, Nagio Takigawa · 2024
Read Prognostic Role of Inflammatory and Nutritional Biomarkers in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors Alone or in Combination with Chemotherapy as First-Line by Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher, Orazio Caffo, Nagio Takigawa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11592697.txt.
Description
Antonello Veccia and co-authors check whether simple blood scores predict survival in advanced lung cancer treated with immune drugs, in a 2024 study. The patients had non small cell lung cancer and got immune checkpoint drugs alone or with chemotherapy as first treatment. Scores built from inflammation and nutrition measures are cheap and widely available.
The review covered 191 patients treated between 2017 and 2024. Higher scores on an inflammation index and a nutrition index both tracked with longer survival. A two part immune score and an inflammation score split patients into groups with widely different outlooks. The pattern held whether or not chemotherapy was added. In layered analysis, the protein albumin on its own also tracked with survival. The authors propose these scores as handy prognostic tools.
Catalog record
| CREATOR | Antonello Veccia, Mariachiara Dipasquale, Stefania Kinspergher, Orazio Caffo, Nagio Takigawa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |